RICARDO
RUIZ VILLAVERDE
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (18)
2024
-
Pityriasis Rubra Pilaris: A Multicentric Case Series of 65 Spanish Patients
Actas Dermo-Sifiliograficas
-
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study
Actas Dermo-Sifiliograficas
-
Repercussion of psoriasis on the emotional health, well-being and quality of life of patients: A descriptive cross-sectional study
Piel, Vol. 39, Núm. 4, pp. 185-192
2023
-
Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus
Acta Dermato-Venereologica, Vol. 103
-
Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population
Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326
-
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525
-
Predictive factors for anti-MDA5 antibody in patients with dermatomyositis: a retrospective multicenter study
JDDG - Journal of the German Society of Dermatology, Vol. 21, Núm. 7, pp. 741-748
-
Prädiktive Faktoren für Anti-MDA5-Antikörper bei Patienten mit Dermatomyositis: eine retrospektive multizentrische Studie
JDDG - Journal of the German Society of Dermatology, Vol. 21, Núm. 7, pp. 741-750
-
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results
Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997
-
[Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T494-T501
2022
-
Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases*
British Journal of Dermatology, Vol. 186, Núm. 1, pp. 142-152
-
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Dermatologic Therapy, Vol. 35, Núm. 2
-
Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group
Journal of Dermatological Treatment
2021
2020
-
Maculopapular eruptions associated to COVID-19: A subanalysis of the COVID-Piel study
Dermatologic Therapy, Vol. 33, Núm. 6
-
Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 34, Núm. 12, pp. 2821-2829
-
The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study
Dermatologic Therapy, Vol. 33, Núm. 6
2019
-
Consensus Statement on the Psychological Needs of Patients With Chronic Inflammatory Skin Diseases
Actas Dermo-Sifiliograficas, Vol. 110, Núm. 2, pp. 102-114